Net sales of the Orion Group came to EUR 496.9 (571.3) million, change -13.0%. The decrease was due to the restructurings as well as lower invoicing in the pharmaceutical wholesale business. Operating profit EUR 29.2 (6.0) million was almost five times higher than in the comparative period. Orion Pharma showed very positive profit performance during the review period. Group profit before extraordinary items and taxes was EUR 29.3 (6.0) million. Earnings per share were EUR 0.29 (0.05). Equity ratio was 46.1 (44.0) %
The figures in the report have not been audited.
Espoo, 17 May 2004
Board of Directors of Orion Corporation
Jukka Viinanen Jari Karlson
President and CEO CFO
The full report including tables can be downloaded from the enclosed link.